pISSN 2234-3806eISSN 2234-3814
Table. 1.
Demographic and clinical characteristics of patients
| Characteristic | Treatment-naive | Receiving antiviral therapy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| IT(N=31) | IA (N=196) | GZ (N=59) | IC (N=49) | P | ETV treatment(N=57) | PEG treatment(N=36) | P | ||
| Age, yrs | 26.0 (24.0, 31.0) | 29.5 (25.0, 34.8) | 31.00(27.0, 38.0) | 32.0(27.5, 39.0) | 0.001 |
33.0(28.0, 39.0) | 29.5(26.0, 31.0) | 0.002 |
|
| Sex | 0.415 |
0.817 |
|||||||
| Male, N (%) | 19 (61.3) | 148 (75.5) | 43 (72.9) | 35 (71.4) | 47 (82.5) | 29 (80.6) | |||
| Female, N (%) | 12 (38.7) | 48 (24.5) | 16 (27.1) | 14 (28.6) | 10 (17.5) | 7 (19.4) | |||
| BMI, kg/m2 | 20.6 (18.4, 22.6) | 21.0 (19.3, 23.0) | 21.2 (19.5, 23.3) | 22.1 (20.2, 23.4) | 0.082 |
21.9(19.5, 24.2) | 20.5(19.3, 22.8) | 0.318 |
|
| Fibroscan, Kpa | 4.75 (4.00, 5.63) | 6.82 (5.53, 10.48) | 4.80 (4.15, 5.50) | 4.70 (4.23, 5.58) | <0.001 |
9.00(7.20, 12.05) | 8.30(6.30, 12.13) | 0.275 |
|
| AST, U/L | 25.0 (21.0, 28.0) | 61.0 (36.0, 108.0) | 26.0(22.0, 31.0) | 24.0(21.0, 29.0) | <0.001 |
96.0(62.0, 148.5) | 68.5(52.8, 109.8) | 0.083 |
|
| ALT, U/L | 24.5 (19.3, 28.8) | 101.0(57.0, 174.0) | 25.5(20.0, 32.0) | 24.0(18.0, 30.0) | <0.001 |
153.0(95.5, 246.0) | 135.0(96.8, 222.0) | 0.705 |
|
| Albumin, g/L | 44.8 (44.0, 47.1) | 44.9(42.5, 47.0) | 46.5(45.5, 47.9) | 46.8(45.1, 48.5) | <0.001 |
44.4(41.7, 46.9) | 43.8(42.5, 45.9) | 0.738 |
|
| Globulin, g/L | 29.3 (26.4, 31.5) | 29.0(26.2, 32.1) | 29.3(26.9, 31.4) | 28.6(27.0, 31.1) | 0.924 |
29.0(26.7, 31.9) | 29.0(25.4, 32.8) | 0.994 |
|
| TBIL, μmol/L | 13.1 (9.5, 18.6) | 15.4(11.7, 20.1) | 12.1(9.3, 15.6) | 12.1(9.4, 16.6) | <0.001 |
16.2(11.7, 21.5) | 17.9(14.2, 22.4) | 0.346 |
|
| HBeAg status | <0.001 |
0.146 |
|||||||
| Negative, N (%) | 0 (0.0) | 44 (22.5) | 49 (83.1) | 46 (93.9) | 8 (14.0) | 1 (2.8) | |||
| Positive, N (%) | 31 (100.0) | 152 (77.6) | 10 (17.0) | 3 (6.1) | 49 (86.0) | 35 (97.2) | |||
| HBV genotype | <0.001 |
NA | |||||||
| B, N (%) | 21 (67.7) | 71 (59.2) | 27 (45.8) | 14 (28.6) | 10 (17.5) | 0 (0.0) | |||
| C, N (%) | 4 (12.9) | 36 (30.0) | 14 (23.7) | 5 (10.2) | 11 (19.3) | 0 (0.0) | |||
| O, N (%) | 3 (9.7) | 5 (4.2) | 3 (5.1) | 2 (4.1) | 0 (0.0) | 0 (0.0) | |||
| NA, N (%) | 3 (9.7) | 8 (6.7) | 15 (25.4) | 28 (57.1) | 36 (63.2) | 36 (100.0) | |||
| HBV DNA, Log IU/mL | 8.23(8.23, 8.23) | 7.88(6.25, 8.23) | 3.76(3.24, 4.48) | 1.86(1.35, 2.97) | <0.001 |
7.98(7.20, 8.23) | 7.70(6.48, 8.19) | 0.081 |
|
| HBsAg, IU/mL | 4.63 (4.45, 4.72) | 4.04(3.42, 4.53) | 3.15(2.28, 3.42) | 2.96(2.04, 3.55) | <0.001 |
4.12(3.60, 4.47) | 3.98(3.27, 4.31) | 0.099 |
|
Data are presented as median (interquartile range) or N (%). All continuous variables did not conform to the normal distribution.
*P-values were calculated using the chi-square test.
†P-values were calculated using the Kruskal–Wallis H test.
‡P-values were calculated using the Mann–Whitney U test.
Abbreviations: IT, immune-tolerant; IA, immune-active; GZ, gray zone; IC, inactive carrier; ETV, entecavir; PEG: Peg-interferon; BMI: body mass index; TBIL: total bilirubin; HBeAg: hepatitis B e antigen; NA, not available; HBsAg: hepatitis B surface antigen.
Ann Lab Med 2025;45:185~198 https://doi.org/10.3343/alm.2024.0178
© Ann Lab Med